Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Mei‐Ching Liu"'
Autor:
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, Tadeusz Pienkowski, Young‐Hyuck Im, Giulia Valeria Bianchi, Barbara Galbardi, Matteo Dugo, Loris De Cecco, Ling‐Ming Tseng, Mei‐Ching Liu, Begoña Bermejo, Vladimir Semiglazov, Giulia Viale, Juan de laHaba‐Rodriguez, Do‐Youn Oh, Brigitte Poirier, Pinuccia Valagussa, Luca Gianni, Elda Tagliabue
Publikováno v:
Molecular Oncology, Vol 16, Iss 12, Pp 2355-2366 (2022)
As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salv
Externí odkaz:
https://doaj.org/article/04d4128992ee4c3590607960b247f2b8
Autor:
Skye Hung-Chun Cheng, Ben-Long Yu, Cheng-Fang Horng, Stella Y. Tsai, Chii-Ming Chen, Nei-Min Chu, Mei-Hua Tsou, Christopher K.J. Lin, Li-Sun Shih, Mei-Ching Liu
Publikováno v:
Journal of Cancer Research and Practice, Vol 3, Iss 1, Pp 1-8 (2016)
Background: This study is to evaluate the associations between long-term survival and stage I breast cancer by examining the hormonal receptor (HR) and human epidermal growth factor receptor-2 (HER2) status. Materials and methods: A total of 1595 bre
Externí odkaz:
https://doaj.org/article/89d1ea80ccbb46a2b2f1e4ad9cc1587b
Autor:
Wei-Hsin Liu, Mei-Ching Liu, Ben-Long Yu, Skye Hung-Chun Cheng, Ming-Yuan Li, Chi-Feng Chung, Tzung-De Wang, Chi-Feng Hung
Publikováno v:
Journal of Cancer Research and Practice, Vol 1, Iss 2, Pp 163-171 (2014)
Trastuzumab, a humanized monoclonal antibody directed against the external domain of the HER-2 protein, has shown remarkable activity against HER-2 positive breast cancer. Consequently, the use of adjuvant trastuzumab plus chemotherapy in patients wi
Externí odkaz:
https://doaj.org/article/40844b67f3e14d0b833ba00c0178181c
Autor:
Mei-ching Liu, 呂玫青
97
There are a lot of available marketing tools to managers, and pricing has been the effective one. Pricing is one of the most important but also most difficult tasks that firms have to make. Nowadays, customers’ preference and purchasing beh
There are a lot of available marketing tools to managers, and pricing has been the effective one. Pricing is one of the most important but also most difficult tasks that firms have to make. Nowadays, customers’ preference and purchasing beh
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/8uqa86
Autor:
Mei-Ching Liu, 劉美青
89
Genomic in situ hybridization (GISH) was used to identify Nicotiana plumbaginifolia -sylvestris aberrant addition lines (4 lines containing a translocated N. sylvestris chromosome and 11 lines containing a deficient N. sylvestris chromosome).
Genomic in situ hybridization (GISH) was used to identify Nicotiana plumbaginifolia -sylvestris aberrant addition lines (4 lines containing a translocated N. sylvestris chromosome and 11 lines containing a deficient N. sylvestris chromosome).
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/40121956879353046677
Autor:
Chiun-Sheng Huang, Guofang Sun, Ling-Ming Tseng, Yi Feng, Kunwei Shen, Youngsen Yang, Ava Kwong, Shusen Wang, Mei-Ching Liu, Ting-Ying Ng, Zhimin Shao, Shin-Cheh Chen, Iris Renfei Yan
Publikováno v:
Breast Cancer Research and Treatment. 187:759-768
In the KATHERINE study (NCT01772472), patients with HER2-positive early breast cancer (EBC) and residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy who were treated with adjuvant trastuzumab emtansine (T-DM1) had a 50%
Autor:
Agostina Stradella, Joanne L. Blum, Sung-Bae Kim, Lee S. Schwartzberg, Sara M. Tolaney, Thomas Wei, Hope S. Rugo, Stew Kroll, Yin-Hsun Feng, Igor Bondarenko, Yann Izarzugaza, Mafalda Oliveira, Noshir Anthony Dacosta, Arlene Chan, Michel Pavic, Mei-Ching Liu, Maria Eva Peréz Lopéz, Elizabeth A. Mittendorf, Samuel Guan Wei Ow, Joe O'Connell
Publikováno v:
Cancer Research. 80:OT1-08
Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pill burden
Autor:
Yann Izarzugaza, Gavin Marx, Igor Bondarenko, Andrew D. Seidman, Mafalda Oliveira, Lee S. Schwartzberg, Joe O'Connell, Yin-Hsun Feng, Sung-Bae Kim, Y.S. Chae, Hope S. Rugo, Julie Lemieux, Joyce O'Shaughnessy, Thomas Wei, Jamil Asselah, Noshir Anthony Dacosta, Mei-Ching Liu, Gail S. Wright
Publikováno v:
Cancer Research. 80:OT1-08
Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel is a novel, oral taxane that has potential advantages over currently available taxanes, including: oral administration with a low pill burden
Autor:
Do-Youn Oh, Barbara Galbardi, Ling-Ming Tseng, Young-Hyuck Im, Tadeusz Pienkowski, Serena Di Cosimo, Giulia Viale, M. Dugo, Vladimir Semiglazov, Loris De Cecco, Begoña Bermejo, Elda Tagliabue, Luca Gianni, Juan de la Haba-Rodriguez, Giulia Bianchi, Mei-Ching Liu, Brigitte Poirier, Tiziana Triulzi, Pinuccia Valagussa, Giampaolo Bianchini
Publikováno v:
Molecular oncology. 16(12)
As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting post-surgical salvage t
Autor:
Do-Youn Oh, Brigitte Poirier, Barbara Galbardi, Giampaolo Bianchini, Giulia Viale, Serena Di Cosimo, Tadeusz Pienkowski, Vladimir Semiglazov, Pinuccia Valagussa, M. Dugo, Elda Tagliabue, Juan de la Haba-Rodriguez, Ling-Ming Tseng, Mei-Ching Liu, Begoña Bermejo, Young Hyuck Im, Giulia Valeria Bianchi, Tiziana Triulzi, L. Gianni, Loris De Cecco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d516099fcb5b2bfe828de1ddae27b31
https://doi.org/10.1002/1878-0261.13141/v2/response1
https://doi.org/10.1002/1878-0261.13141/v2/response1